CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia

Journal of Immunotherapy

Volumn 24, Issue 3, 2001, Pages 272-279

  Treon, Steven P ^a   Agus, David B ^a   Link, Brian ^a   Rodrigues, Gilberto ^a   Molina, Arturo ^a   Lacy, Martha Q ^a   Fisher, David C ^a   Emmanouilides, Christos ^b   Richards, Arthur I ^b   Clark, Bruce ^b   Lucas, Marjorie S ^b   Schlossman, Robert ^b   Schenkein, David ^b   Lin, Boris ^b   Kimby, Eva ^b   Anderson, K C ^b   Byrd, John C ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Antibody mediated immunotherapy; Lymphoplasmacytic lymphoma; Rituximab; Serotherapy; Waldenstrom's macroglobulinemia

Indexed keywords

CD20 ANTIGEN; IMMUNOGLOBULIN M; RITUXIMAB; STEROID;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; FEVER; HEMATOCRIT; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT OUTCOME; URTICARIA; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BONE MARROW; FEMALE; HUMANS; IMMUNOGLOBULIN M; IMMUNOTHERAPY; LYMPHATIC DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPLENOMEGALY; WALDENSTROM MACROGLOBULINEMIA;

EID: 0034999927     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200105000-00012     Document Type: Article

References (20)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18:214-26.
2. Leo R, Boeker M, Peest D, et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol 1992; 64:132-9.
3. Jensen GS, Andrews EJ, Mant MJ, Vergidis R, Ledbetter JA, Pilarski LM. Transitions in CD45 isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom's macroglobulinemia. Am J Hematol 1991; 37:20-30.
4. Pilarski LM, Masellis-Smith A, Szczepek A, Mant MJ, Belch AR. Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leuk Lymphoma 1996; 22:375-83.
5. Takishita M, Kosaka M, Goto T, Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies. Br J Haematol 1994; 87:735-42.
6. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000; 27:598-613.
7. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33.
8. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45.
9. Maloney D, Smith B, Appelbaum F. The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88:637a.
10. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91:1644-52.
11. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10:1525-7.
12. Weber DM, Gavino M, Huh Y, Cabanillas F, Alexanian R. Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia. Blood 1999; 94:125a.
13. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-24.
14. Treon SP, Shima Y, Preffer FI, et al. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Semin Oncol 1999; 26:97-106.
15. Byrd JC, Grever MR, Davis B, et al. Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a feasible and active regimen. Blood 1999; 94:704a.
16. Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109:81-8.
17. Demidem A, Hanna N, Hariharan H, Bonavida B. Chimeric anti-CD20 antibody (IDEC-C2B8) is apoptotic and sensitizes drug resistant human B cell lymphomas and AIDS related lymphomas to CDDP, VP-16 and toxins. FASEB J 1995; 9:A206.
18. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10:655-61.
19. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-76.
20. Hussein MA, Karam MA, McLain DA, Elson P, Hsi E. Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma patients. Blood 1999; 94:313a.